Unresectable hepatocellular carcinoma (HCC)
Conditions
Interventions
Observation group:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Pathologically or clinically diagnosed with hepatocellular carcinoma (HCC) and unresectable; (2) Aged 18–75 years; (3) At least one measurable lesion per mRECIST 1.1 criteria; (4) Liver function classified as Child-Pugh Grade A or B [see Child-Pugh Classification Criteria (Table 1)]; (5) Complete clinical and follow-up data.
Exclusion criteria
Exclusion criteria: (1) No CT or MRI imaging data available before TACE treatment or 1 month after surgery; (2) Cases lost to follow-up within 1 month after TACE treatment; (3) Patients with extrahepatic metastasis or concurrent other tumors; (4) Severe liver dysfunction, uncorrectable coagulation disorders, complete obstruction of the main portal vein by tumor thrombus, or significant reduction in peripheral blood leukocytes and platelets (WBC < 3.0×10^9/L, PLT < 50×10^9/L) at the time of treatment; (5) Concurrent severe cardiorenal insufficiency, etc.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS);Progression-free survival (PFS);Duration of ongoing remission (DOR);Disease Control Rate (DCR);Safety; | — |
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Countries
China
Contacts
Public ContactChang Liu
West China Hospital of Sichuan University
Outcome results
None listed